Agenida Sponsored EMJ Webinars


Emj

Genomic Profiling of Breast Cancer: A Multidisciplinary approach in early stage breast cancer treatment decisions



WEBINAR OBJECTIVES:

Upon completion of this webinar, participants should be able to:

  • Understand the latest data supporting the utility of Agendia’s assays: MammaPrint and BluePrint for early-stage breast cancer patients
  • Review and appreciate the real-world impact of MammaPrint and BluePrint
  • Recommend genomic profiling for pre-and post-operative breast cancer treatment planning

Recorded on Tuesday 21st June – 8 AM PST


View The Recorded Webinar Here

About the speakers

William Audeh, MD, MS
Chief Medical Officer, Agendia
William Audeh, Agendia’s Chief Medical Officer, is a medical oncologist specializing in breast cancer, with nearly 30 years of experience as a clinician and clinical researcher at the Cedars-Sinai Cancer Center in Los Angeles. Prior to joining Agendia, and in addition to his clinical practice, he served as the former Director of the Cedars-Sinai Cancer Center and Medical Director of the Wasserman Breast Cancer Risk Reduction Program. Dr. Audeh has been Principal Investigator on a wide variety of national and international clinical and translational trials, and has authored numerous publications in the field of breast cancer, cancer genomics and targeted cancer therapy.

Cathy L. Graham, MD, FACS

Cathy L. Graham, MD, FACS is an Assistant Professor of Surgery in the Division of Surgical Oncology of the Department of Surgery at Emory University School of Medicine and is the Director of Breast Surgery at Emory Saint Joseph’s Hospital in Atlanta, Georgia. A board-certified breast surgeon, Dr. Graham’s clinical interests include benign and malignant breast disease, breast cancer risk assessment, risk modification and personalized breast cancer treatment. She has over 25 years of experience in breast surgery. She holds special certification in breast ultrasound, ultrasound guided biopsy and stereotactic biopsy. She is actively involved in clinical research through her affiliation with Winship Cancer Institute and is a Principal Investigator for the FLEX Trial.

Previously EMJ Webinars

“From Diagnosis to Endocrine Management: Utilizing Genomic Profiling to Inform Comprehensive Treatment Planning for Women With Early Stage Breast Cancer”



WEBINAR OBJECTIVES:

Upon completion of this webinar, participants should be able to:

  • Understand the latest data supporting the utility of Agendia’s assays: MammaPrint® and BluePrint® for ER+ patients.
  • Review and appreciate the real-world impact of MammaPrint and BluePrint.
  • Recommend genomic profiling for pre-and post-operative breast cancer treatment planning

 

Recorded on Thursday 30th September – 11 AM EST


View The Recorded Webinar Here

About the speakers

William Audeh, MD, MS
Chief Medical Officer, Agendia
William Audeh, MD, MS is a medical oncologist specializing in breast cancer, with nearly 30 years of experience as a clinician and clinical researcher at the Cedars-Sinai Cancer Center in Los Angeles. Prior to joining Agendia, and in addition to his clinical practice, he served as the former Director of the Cedars-Sinai Cancer Center and Medical Director of the Wasserman Breast Cancer Risk Reduction Program. Dr. Audeh has been Principal Investigator on a wide variety of national and international clinical and translational trials, and has authored numerous publications in the field of breast cancer, cancer genomics and targeted cancer therapy.

Alberto Montero, MD, MBA, CPHQMD

Alberto Montero, MD, MBA, CPHQ, is clinical director of the Breast Cancer Medical Oncology Program at University Hospitals Seidman Cancer Center and an associate professor of medicine at Case Western Reserve University School of Medicine. He is board certified in medical oncology by the American Board of Internal Medicine. Dr. Montero has been in academic practice for over 13 years and has demonstrated a strong track record of clinical research in breast cancer. Prior to joining the UH Seidman Cancer Center team, Dr. Montero spent seven years at the Cleveland Clinic, where he served as a staff physician in the hematology and oncology department, as well as chief quality improvement officer and patient experience officer. Before that, Dr. Montero was on staff at University of Miami Sylvester Cancer Center as Breast Cancer Site Disease Group co-leader, and at the Medical University of South Carolina Division of Hematology/Oncology.

FOR PROVEN RESULTS

Trusted by leading physicians and institutions around the world

Our Tests

At the genomic level, physicians can examine the activity of specific genes inside a tumor – how they interact to drive the behavior of a tumor.

View More Information
Genomic Testing Cell Photo

Landmark Studies

Data on the validation and utility of MammaPrint and BluePrint for patients with early stage breast cancer.

View More Information
Two women reading about genomic breast cancer results

Latest News

The most recent data and news from Agendia to keep you up-to-date on how our tests can support you and your patients.

Read the article